GHRS Company Profile and Key Details

Q: Who are the executives of GHRS?

Ms. Julie Ryan F.C.A.Vice President of Fin.Dr. Theis Terwey M.D.Co-Founder & Chief Executive OfficerMr. Aaron CameronVice President of Technical Devel. & Operational PlanningMr. Theis Terwey M.D.Co-Founder & Chief Executive OfficerMs. Julie Ryan A.C.A.Vice President of Fin.Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive ChairmanMr. Magnus HalleCo-Founder & MD of Ireland

NASDAQ : GHRS

GH Research

$22.09

-0.15-0.67%

At Close 4:00 PM

58.75

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

GH Research PLC (GHRS) stock declined over -0.67%, trading at $22.09 on NASDAQ, down from the previous close of $22.24. The stock opened at $22.85, fluctuating between $21.69 and $23.21 in the recent session.

Stock Snapshot

22.24

Prev. Close

1.51B

Market Cap

21.69

Day Low

-24.27

P/E Ratio

-0.91

EPS (TTM)

-0.64

Cash Flow per Share

22.85

Open

68.56M

Number of Shares

23.21

Day High

67.61%

Free Float in %

4.21

Book Value

759.91K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	22.85	23.21	21.69	22.09	763.08K
Jun 18, 2026	21.99	23.03	21.30	22.24	544.57K
Jun 17, 2026	19.96	21.77	19.96	21.70	177.8K
Jun 16, 2026	20.26	20.38	19.52	19.98	131.55K
Jun 15, 2026	21.57	21.58	20.12	20.37	159.36K
Jun 12, 2026	20.85	22.06	20.68	21.12	180.73K
Jun 11, 2026	20.54	21.16	20.00	20.66	217.78K
Jun 10, 2026	20.16	21.32	20.00	20.36	140.66K
Jun 09, 2026	20.44	21.60	19.75	20.35	259.86K
Jun 08, 2026	21.68	22.24	19.74	20.12	379.06K
Jun 05, 2026	23.01	23.61	21.21	21.43	329.9K
Jun 04, 2026	24.35	25.31	23.08	23.25	275.98K
Jun 03, 2026	24.84	24.85	23.85	24.43	139.13K
Jun 01, 2026	23.96	25.24	23.04	24.83	282.83K
May 29, 2026	22.40	24.25	22.02	23.99	318.36K
May 28, 2026	22.42	22.95	21.90	22.38	122.12K
May 27, 2026	23.15	23.89	22.15	22.36	189.23K
May 26, 2026	22.37	23.23	21.81	23.15	301.5K
May 22, 2026	21.81	23.84	21.81	22.12	314.85K
May 21, 2026	22.40	22.60	21.64	21.77	310.14K

Contact Details

Dublin, D02 NX43

Ireland

https://www.ghres.com 353 143 78443

About Company

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

GH Research PLC (NASDAQ:GHRS) closed at $22.09 USD, losing -$0.15 (-0.67%) from the previous close of $22.24. The stock is currently mid-range between its 52-week high and low $11.32 and $25.94. With a market capitalization of about $1.51 billion, GH Research PLC is classified as a small-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 241.39 thousand shares, trading with heavier-than-usual volume. Headquartered in Dublin, None, GH Research PLC operates in the Healthcare sector and the Biotechnology industry. Led by CEO Velichka Valcheva, the company employs approximately 50 people and listed since June 25, 2021. GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions.

Technical Performance

GHRS has shown sold momentum, gaining 3.55% over the past week and 16.75% over the past quarter, though year-to-date performance is up 24.02%. Short-term trend indicators are bearishly aligned (SMA20 1.12%, SMA50 4.3%, SMA200 12.78%). The stock’s 14-day RSI is 51.54 (neutral), while the ATR of 0.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.89% below its high and over 95.86% above its low. Average 10-day trading volume of 355.27 thousand shares is slightly above the 3-month average of 241.46 thousand, indicating heightened recent market interest.

Valuation Metrics

GH Research PLC trades at a P/E ratio of -24.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.22 trading at moderately above to book value. The P/FCF stands at -32.65, also below market averages.

Dividend & Fair Value

GH Research PLC last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

GH Research PLC generated EPS of -$0.73 over the past year. Five-year average earnings growth is -179.37%. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.27. Next year's EPS is expected at -$39.76. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $19.00. The high target offers 216.89% upside. The low target suggests -13.99% downside. The mean target is $38.69. This offers 75.15% upside. GH Research PLC earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by 14.81%. The prior quarter beat by -20.69%. Over the last six quarters, Apple has recorded several small beats. These include -26.09% in February 27, 2025.

Shareholding & Insider Activity

GH Research PLC has 62.03 million shares outstanding. The public float is 20.47 million shares, elevated short interest at 13.27% of float. This equals 2.30 million shares. The short ratio is 6.42 days. Institutional investors hold 102.74% of the float. Insiders own 31.46%.

Financial & Profitability Overview

Over the trailing twelve months, GH Research has not generated any revenue. Returns are negative, with ROA at -15.73% and ROE at -16.25%.
On valuation metrics, GH Research trades at a P/E of -24.08, P/S of 0.00 and P/B of 5.22. The current ratio is 23.04 and quick ratio is 23.04. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -7098.49 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -107.25.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, GH Research posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $315.00K (margin 0.00%). Operating income was - $41.22M (margin 0.0%). Net income was- $35.59M (EPS - $0.68).
The company ended the quarter with $161.56M in cash and short-term investments, a total debt of $343.00K, and net debt of - $78.08M. Total assets were $226.30M, with equity of $218.97M. Financials further reflected weakness, with operating cash flow of - $33.34M, free cash flow of - $33.44M, and capital expenditures of - $100.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that GH Research PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.66%, with price expected at $21.06 by July 06, 2026, within a range of $19.82 to $22.27 3-Month Outlook: Projected fall of -28.66%, reaching $15.76 by September 18, 2026, with a range of $13.98 to $17.07. 1-Year Outlook: Projected gain of 7.83%, with price at $23.82 by June 22, 2027, within a range of $22.78 to $24.88.

Key Takeaways

GH Research PLC (NASDAQ:GHRS) shares are up 24.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows GH Research PLC trading at a premium to the broader market with a P/E of -24.08. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.12, suggesting 72.57% upside. Our AI forecast model points to short-term weakness (-4.66% over two weeks), a medium-term fall (-28.66% over three months), and a longer-term gain (7.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current GH Research PLC (GHRS) stock price?

GH Research PLC (NASDAQ: GHRS) stock price is $22.09 in the last trading session. During the trading session, GHRS stock reached the peak price of $23.21 while $21.69 was the lowest point it dropped to. The percentage change in GHRS stock occurred in the recent session was -0.67% while the dollar amount for the price change in GHRS stock was - $0.15.

GHRS's industry and sector of operation?

The NASDAQ listed GHRS is part of Biotechnology industry that operates in the broader Healthcare sector. GH Research PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GHRS?

Ms. Julie Ryan F.C.A.
Vice President of Fin.
Dr. Theis Terwey M.D.
Co-Founder & Chief Executive Officer
Mr. Aaron Cameron
Vice President of Technical Devel. & Operational Planning
Mr. Theis Terwey M.D.
Co-Founder & Chief Executive Officer
Ms. Julie Ryan A.C.A.
Vice President of Fin.
Mr. Florian Schonharting M.Sc. (Econ)
Co-Founder & Non-Executive Chairman
Mr. Magnus Halle
Co-Founder & MD of Ireland

How GHRS did perform over past 52-week?

GHRS's closing price is 95.14% higher than its 52-week low of $11.32 where as its distance from 52-week high of $25.94 is -14.84%.

How many employees does GHRS have?

Number of GHRS employees currently stands at 50.

Link for GHRS official website?

Official Website of GHRS is: https://www.ghres.com

How do I contact GHRS?

GHRS could be contacted at phone 353 143 78443 and can also be accessed through its website. GHRS operates from 28 Baggot Street Lower, Dublin, D02 NX43, Ireland.

How many shares of GHRS are traded daily?

GHRS stock volume for the day was 759.91K shares. The average number of GHRS shares traded daily for last 3 months was 241.39K.

What is the market cap of GHRS currently?

The market value of GHRS currently stands at $1.51B with its latest stock price at $22.09 and 68.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	50
Beta	1.31
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GHRS Company Profile and Key Details

GH Research

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways